Targeting Functional Noncoding RNAs in CML With Cas9

Share this content:
A new screening approach identifies more than 200 lncRNAs essential for survival in CML cells, suggesting lncRNAs could be good prospective targets for therapies.
A new screening approach identifies more than 200 lncRNAs essential for survival in CML cells, suggesting lncRNAs could be good prospective targets for therapies.

A new library of Cas9 single-guide RNAs (sgRNAs) can knock out long noncoding RNAs (lncRNAs) by targeting splice sites. Using the novel screening technique, investigators at Peking University, Beijing, China, reported in Nature Biotechnology that they had identified 230 lncRNAs essential for survival in a chronic myeloid leukemia (CML) cell line.1

Noncoding RNAs contribute significantly to disease, but have been tricky to study because they don't code for proteins. “We came up with this idea to try to tackle the splicing sites,” says Wensheng Wei, PhD, professor at Peking University, who led the study. Dr Wei is also the founder of EdiGene, Inc, as well as the vice director of the Chinese Association of Gene Editing. “When we target [the splice sites] using single-guide RNA, we can get either intron retention or exon skipping, basically interrupt the RNA splicing.” Exon skipping introduces huge deletions in transcript, and retaining large introns can interfere with the RNA being able to resume its proper conformation.

Continue Reading Below

Typically, a CRISPR–Cas9 screening library introduces cuts, creating frameshift mutations that disrupt the protein sequence and cause a loss of function. In lncRNAs, there's no reading frame, so frame-shift mutations are meaningless; gene knockout cannot occur.

Dr Wei's group first approached the problem by using paired gRNAs to chop out sections within the noncoding gene, knocking it out. But introducing 2 guide RNAs each time created a technological barrier to scaling up, he said.

Another approach, published by researchers at the University of California, San Francisco (UC San Francisco), is to use CRISPR interference (CRISPRi) to prevent the lncRNA from being transcribed. This technique employs a deactivated form of Cas9 that binds, but doesn't cut, the DNA, blocking transcription. The downside of this approach, however, is that it can also inhibit transcription of nearby genes.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs